GSK3B and renal cell carcinoma: The results demonstrate low miR-199a expression as a feature of advanced renal cell carcinoma, identify miR-199a as a negative regulator of GSK-3β, and suggest re-expression of pre-miR-199a as a new potential treatment of renal cell carcinoma.